Carnitine palmitoyltransferase 1A (CPT1A) inhibitors, like ST1326, have demonstrated early clinical success by weakening tumor cell survival under hypoxic and nutrient‐deprived conditions through fatty acid oxidation (FAO) inhibition (Figure 3) [136]. Here, CPT1A is linked to neoplasm.